> Adolor [1] has decided to stop its work on a pain patch licensed three years [2] ago and will hand it back to EpiCept. Adolor says it wants to devote its resources to other development projects. Report [3]

> The San Jose Mercury News profiles Dynavax's [4] work in developing a universal flu vaccine. Article [5]

> Charles River Laboratories [6] has acquired Northwest Kinetics, a 150-bed facility engaged in branded drug studies, for $29.5 million. Report [7]

> Regeneron Pharmaceuticals' [8] IL-1 Trap hit its primary endpoints in a Phase III trial for CIAS1-related autoinflammatory periodic syndromes, or CAPS Regeneron says its will ask the FDA for approval in the second quarter of next year. Report [9]

> The European Commission has granted CytRx's ALS drug arimoclomol orphan drug status. Release [10]

> Sigma Pharmaceuticals has increased its bid for Australian Pharmaceutical Industries. Report [11]

> Human Genome Sciences is touting positive data from a mid-stage trial of its hepatitis drug Albuferon with ribavarin. Report [12]

And Finally… Harvard biologist Marc D. Hauser believes that evolution has programmed our essential views of morality into our neural circuits. Article [13]